Tedopi: Phase III started

Orphan Synergy Europe began the open-label, international Phase III ATALANTE 1 trial to compare subcutaneous Tedopi vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Patients wi...